Reuters logo
BRIEF-Xenon acquires potassium channel modulator epilepsy treatment
April 26, 2017 / 10:42 AM / 6 months ago

BRIEF-Xenon acquires potassium channel modulator epilepsy treatment

April 26 (Reuters) - Xenon Pharmaceuticals Inc:

* Xenon Pharmaceuticals inc says phase 2 proof-of-concept clinical trial beginning in mid-2018

* Xenon expands ion channel neurology pipeline with acquisition of new potassium channel modulator for the treatment of epilepsy

* Xenon Pharmaceuticals Inc - Xenon anticipates filing an IND, or IND equivalent, to initiate a phase 1 first-in-man clinical trial in Q4 of 2017

* Xenon Pharmaceuticals inc says anticipates filing an IND, or IND equivalent, to initiate a phase 1 first-in-man clinical trial in q4 of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below